Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Sandborn

Showing results (171-180 of 186) with videos related to

Pageof 19
Sort By:
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Alimentary Pharmacology & Therapeutics|November 14, 1997
A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administrationR F Compton, W J Sandborn, G M Lawson, et al.
Alimentary Pharmacology & Therapeutics|January 26, 2013
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel diseaseJ B Kisiel, T C Yab, F T Nazer Hussain, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Gastroenterology|October 26, 2001
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulasD A Schwartz, M J Wiersema, K M Dudiak, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's diseaseM A Samaan, C A J Puylaert, B G Levesque, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitisG R D'Haens, W J Sandborn, G Zou, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2016
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitisW J Sandborn, B R Bhandari, R Fogel, et al.
Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:
Pageof 19
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Alimentary Pharmacology & Therapeutics|November 14, 1997
A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administrationR F Compton, W J Sandborn, G M Lawson, et al.
Alimentary Pharmacology & Therapeutics|January 26, 2013
Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel diseaseJ B Kisiel, T C Yab, F T Nazer Hussain, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Gastroenterology|October 26, 2001
A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulasD A Schwartz, M J Wiersema, K M Dudiak, et al.
Alimentary Pharmacology & Therapeutics|June 28, 2017
The development of a magnetic resonance imaging index for fistulising Crohn's diseaseM A Samaan, C A J Puylaert, B G Levesque, et al.
Alimentary Pharmacology & Therapeutics|June 2, 2017
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitisG R D'Haens, W J Sandborn, G Zou, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Alimentary Pharmacology & Therapeutics|May 25, 2016
Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitisW J Sandborn, B R Bhandari, R Fogel, et al.
Pageof 19